Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin

[1]  A. Brancale,et al.  The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. , 2009, Journal of medicinal chemistry.

[2]  J. Balzarini,et al.  Successful kinase bypass with new acyclovir phosphoramidate prodrugs. , 2008, Bioorganic & medicinal chemistry letters.

[3]  W. Lipscomb,et al.  Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. , 2007, Journal of the American Chemical Society.

[4]  A. Brancale,et al.  Molecular Modelling Studies on the Binding of Some Protides to the Putative Human Phosphoramidase Hint1 , 2007, Nucleosides, nucleotides & nucleic acids.

[5]  C. Mcguigan,et al.  Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. , 2007, Journal of medicinal chemistry.

[6]  William A. Lee,et al.  Cathepsin A Is the Major Hydrolase Catalyzing the Intracellular Hydrolysis of the Antiretroviral Nucleotide Phosphonoamidate Prodrugs GS-7340 and GS-9131 , 2006, Antimicrobial Agents and Chemotherapy.

[7]  E. De Clercq,et al.  Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin. , 2006, Biochemical and biophysical research communications.

[8]  E. De Clercq,et al.  The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication , 2006, Molecular Pharmacology.

[9]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A , 2005 .

[10]  E. De Clercq,et al.  Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. , 2005, Journal of medicinal chemistry.

[11]  E. De Clercq,et al.  The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase , 2005, Journal of Virology.

[12]  Jean-Louis Romette,et al.  A Structural Basis for the Inhibition of the NS5 Dengue Virus mRNA 2′-O-Methyltransferase Domain by Ribavirin 5′-Triphosphate* , 2004, Journal of Biological Chemistry.

[13]  Ralf Bartenschlager,et al.  A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. , 2003, Journal of virological methods.

[14]  Charles Brenner,et al.  Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. , 2002, Biochemistry.

[15]  C. Cameron,et al.  Quasispecies, error catastrophe, and the antiviral activity of ribavirin. , 2002, Virology.

[16]  E. De Clercq,et al.  Synthesis and Antiviral Evaluation of Phosphoramidate Derivatives of (E)-5-(2-Bromovinyl)-2′-Deoxyuridine , 2001, Antiviral chemistry & chemotherapy.

[17]  N. Snell.  Ribavirin - current status of a broad spectrum antiviral agent , 2001, Expert opinion on pharmacotherapy.

[18]  M. Andreoni,et al.  A randomized 4‐arm multicenter study of interferon alfa–2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone , 2001, Hepatology.

[19]  C. Cameron,et al.  RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Bergamini,et al.  Treatment with ribavirin and interferon‐α reduces interferon‐γ expression in patients with chronic hepatitis C , 2001 .

[21]  J. Arnold,et al.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Network Boston.

[22]  E. De Clercq,et al.  Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. , 1999, Molecular pharmacology.

[23]  O. Weiland,et al.  The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. , 1998, The Journal of general virology.

[24]  Vincent C. Emery,et al.  J. Virol. Methods , 1996 .

[25]  J. Balzarini,et al.  Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells , 1996 .

[26]  E. De Clercq,et al.  Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. , 1996, Journal of medicinal chemistry.

[27]  D. Carson,et al.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Philipson,et al.  Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate , 1977, Antimicrobial Agents and Chemotherapy.

[29]  R. K. Robins,et al.  Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides , 1972 .

[30]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[31]  T. Nyholm,et al.  Nucleosides Nucleotides Nucleic Acids , 2003 .

[32]  R. Noyori,et al.  O-selective phosphorylation of nucleosides without N-protection , 1993 .

[33]  V. Georgiev.  Virology , 1955, Nature.